Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Pandox in connection with a directed share issue of approximately SEK 3 billion
Mandate

Vinge has advised Pandox in connection with a directed share issue of approximately SEK 3 billion

November 06, 2019 Capital Markets and Public M&A

Vinge has advised the hotel property owner Pandox in connection with a directed share issue of 16,350,000 class B shares, whereby Pandox will receive approximately SEK 3 billion in issue proceeds.

The subscription price was determined to SEK 186.50 per share through an accelerated book building process. The share issue was directed to approximately 130 Swedish and international institutional investors. The purpose of the share issue is increase the financial flexibility for additional acquisitions and further strengthen the company’s competitive position in the international hotel property market.

Vinge’s team consisted of Jesper Schönbeck, Nils Fredrik Dehlin and Hampus Olsson.

Related

Vinge advises Oncorena in connection with share issue

 Vinge advises Oncorena Holding AB in connection with a share issue of approximately SEK 133 million.
July 30, 2025

Vinge advises Karl Hedin and minority owners on the sale of AB Karl Hedin Sågverk to Vida

 Vinge has advised Karl Hedin and minority shareholders in connection with the sale of AB Karl Hedin Sågverk to Vida Aktiebolag (“Vida”).
July 24, 2025

Vinge advises OsteoCentric on the public offer for Integrum

 OsteoCentric Oncology and Bone Anchored Prostheses, LLC, a subsidiary of OsteoCentric Technologies, Inc., has made a public offer for all shares in Integrum AB (publ). The offer values all shares in Integrum at approximately SEK 939 million.
July 23, 2025